Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...
Novo Nordisk's anti-TFPI antibody concizumab has ... Alhemo – is already approved in other markets, including Japan, Australia, and Switzerland, but was rejected by the FDA last year with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback